Antibody-drug conjugates (ADCs) have come a long way in recent years. Tubulis wants to advance the modality still further—and has pulled in 60 million euros ($63 million) to bankroll technology to ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

Pfizer PFE has strengthened its R&D pipeline through M&A deals and clinical trial success over the past decade. Pfizer has ...

MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life ...

We recently published 11 Best Cancer Stocks to Buy Right Now.Merck & Co., Inc. is one of them. Merck & Co., Inc. (NYSE:MRK) ...

Sutro Biopharma, Inc. announced a strategic shift in its focus towards its next-generation antibody drug conjugate (ADC) portfolio following a strategic review, reprioritizing its pipeline to ...

Analyst Kaveri Pohlman of BTIG maintained a Buy rating on Genmab (GMAB – Research Report), retaining the price target of $46.00. Kaveri Pohlman’s rating is based on Genmab’s strategic move to acquire ...

-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...

MUNICH--(BUSINESS WIRE)--Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and ...

SUZHOU, China, May 4, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), announced today that its subsidiary, Levena Biopharma Co., Ltd ...